MediWound (NASDAQ:MDWD) Posts Quarterly Earnings Results, Beats Estimates By $0.57 EPS

MediWound (NASDAQ:MDWD) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.57, Zacks reports. The business had revenue of $5.43 million for the quarter, compared to analyst estimates of $6.56 million. MediWound had a negative net margin of 142.18% and a negative return on equity of 96.71%.

MediWound Stock Performance

Shares of MDWD opened at $16.86 on Friday. MediWound has a 1 year low of $14.14 and a 1 year high of $22.50. The company’s 50 day simple moving average is $18.04 and its 200 day simple moving average is $18.83. The company has a market capitalization of $186.93 million, a price-to-earnings ratio of -6.39 and a beta of 0.22.

Wall Street Analysts Forecast Growth

MDWD has been the subject of a number of research reports. Weiss Ratings restated a “sell (d-)” rating on shares of MediWound in a research report on Wednesday, October 8th. Zacks Research raised shares of MediWound from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 11th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $36.00 target price (up previously from $31.00) on shares of MediWound in a research note on Friday. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, MediWound presently has an average rating of “Moderate Buy” and an average target price of $33.50.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Millennium Management LLC boosted its holdings in shares of MediWound by 355.6% during the third quarter. Millennium Management LLC now owns 175,383 shares of the biopharmaceutical company’s stock worth $3,160,000 after purchasing an additional 136,884 shares during the last quarter. UBS Group AG lifted its position in MediWound by 15.3% during the third quarter. UBS Group AG now owns 76,301 shares of the biopharmaceutical company’s stock worth $1,375,000 after buying an additional 10,102 shares during the period. Sargent Investment Group LLC lifted its position in MediWound by 11.1% during the third quarter. Sargent Investment Group LLC now owns 59,926 shares of the biopharmaceutical company’s stock worth $1,080,000 after buying an additional 6,000 shares during the period. The Manufacturers Life Insurance Company boosted its stake in MediWound by 104.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,062 shares of the biopharmaceutical company’s stock worth $505,000 after buying an additional 13,312 shares during the last quarter. Finally, Marshall Wace LLP purchased a new stake in MediWound in the 2nd quarter valued at about $317,000. Hedge funds and other institutional investors own 46.83% of the company’s stock.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.